Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Community Research Initiative of New England |
---|---|
Information provided by: | Community Research Initiative of New England |
ClinicalTrials.gov Identifier: | NCT00543101 |
This study will evaluate patients who have achieved virologic suppression (< 400 copies/mL) on any dual protease inhibitor (PI) combination, to determine whether patients can substitute both PIs with the single boosted PI darunavir given 600/100 ritonavir (RTV) twice daily (BID) and maintain comparable virologic suppression (% < 50 c/mL) for 24 weeks.
Condition | Intervention | Phase |
---|---|---|
HIV Infections |
Drug: dual boosted protease inhibitor Drug: darunavir |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Controlled Trial to Evaluate the Efficacy of Substituting Darunavir/Ritonavir (DRV/r) for Dual-Boosted Protease Inhibitors in Individuals With Virologic Suppression for at Least 12 Weeks |
Estimated Enrollment: | 60 |
Study Start Date: | October 2007 |
Estimated Study Completion Date: | January 2009 |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
Switch to DRV/r at a dose of 600/100 BID for 48 weeks
|
Drug: dual boosted protease inhibitor
dual boosted protease inhibitor
|
2: Active Comparator
Continue on current dual boosted PI until week 24. At week 24, participants will be allowed to cross over to the DRV/r arm provided that they have maintained virologic suppression (< 400 copies/ml) for the first 24-weeks of the study and are followed for an additional 24 weeks
|
Drug: darunavir
darunavir
|
The purpose of this study is to determine if patients who have achieved virologic suppression (< 400 copies/mL) on any dual PI combination, can substitute both PIs with the single boosted PI darunavir given 600/100 rtv bid and maintain comparable virologic suppression (% < 50 c/mL) for 24 weeks. Randomized, non-blinded, multicenter, 48 week, controlled trial to assess the non-inferiority of substituting DRV/r for a dual boosted PI combination in patients with stable virologic suppression on a regimen containing a dual boosted PI combination plus at least one additional FDA-licensed antiretroviral agent from another class. Participants will be randomized (1:1) to one of the included treatment arms.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Any grade 3 or 4 toxicity with the following exceptions:
Note: Hormonal based contraception may not be reliable when taking darunavir, therefore to be eligible for this study, women of childbearing potential who may have vaginal intercourse should either:
United States, Arizona | |
Spectrum Medical Group | |
Phoenix, Arizona, United States, 85012 | |
United States, California | |
AIDS Healthcare Foundation | |
Los Angeles, California, United States, 02319 | |
United States, Florida | |
Orlando Immunology Center | |
Orlando, Florida, United States | |
United States, Massachusetts | |
Community Research Initiative of New England | |
Boston, Massachusetts, United States, 02215 | |
United States, New York | |
Albany Medical Center | |
Albany, New York, United States, 12208 |
Principal Investigator: | Calvin J Cohen, MD, MSc | CRI |
Study ID Numbers: | 07-142 |
Study First Received: | October 11, 2007 |
Last Updated: | October 9, 2008 |
ClinicalTrials.gov Identifier: | NCT00543101 |
Health Authority: | United States: Institutional Review Board |
HIV/AIDS darunavir Protease inhibitors Dual boosted Treatment experienced |
Virus Diseases Sexually Transmitted Diseases, Viral Ritonavir HIV Infections Sexually Transmitted Diseases |
Acquired Immunodeficiency Syndrome Retroviridae Infections Darunavir Immunologic Deficiency Syndromes |
Anti-Infective Agents RNA Virus Infections HIV Protease Inhibitors Slow Virus Diseases Anti-HIV Agents Immune System Diseases Molecular Mechanisms of Pharmacological Action Enzyme Inhibitors |
Infection Antiviral Agents Pharmacologic Actions Protease Inhibitors Anti-Retroviral Agents Therapeutic Uses Lentivirus Infections |